92 related articles for article (PubMed ID: 27543658)
1. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
Quiros-Roldan E; Raffetti E; Castelli F; Focà E; Castelnuovo F; Di Pietro M; Gagliardini R; Gori A; Saracino A; Fornabaio C; Sighinolfi L; Di Filippo E; Maggiolo F; Donato F
J Antimicrob Chemother; 2016 Dec; 71(12):3519-3527. PubMed ID: 27543658
[TBL] [Abstract][Full Text] [Related]
2. Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
Chirouze C; Journot V; Le Moing V; Raffi F; Piroth L; Reigadas S; Cassuto JP; Chêne G; Leport C; Hoen B;
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):204-8. PubMed ID: 25590273
[TBL] [Abstract][Full Text] [Related]
3. Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?
Wang R; Haberlen SA; Palella FJ; Mugavero MJ; Margolick JB; Macatangay BJC; Martínez-Maza O; Jacobson LP; Abraham AG
AIDS; 2018 Nov; 32(17):2547-2556. PubMed ID: 30379686
[TBL] [Abstract][Full Text] [Related]
4. Copy-Years Viremia and Risk of Virological Failure in Long-Term-Treated HIV Patients.
Falasca F; De Vito C; Mazzuti L; di Carlo D; Celani L; Fimiani C; dʼEttorre G; Mezzaroma I; Antonelli G; Turriziani O
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):423-428. PubMed ID: 30531307
[TBL] [Abstract][Full Text] [Related]
5. Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.
Wright ST; Hoy J; Mulhall B; Oʼconnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA
J Acquir Immune Defic Syndr; 2014 May; 66(1):55-64. PubMed ID: 24463783
[TBL] [Abstract][Full Text] [Related]
6. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
[TBL] [Abstract][Full Text] [Related]
7. Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana.
Kukoyi O; Renner L; Powell J; Barry O; Prin M; Kusah J; Cong X; Paintsil E
BMC Infect Dis; 2016 Feb; 16():58. PubMed ID: 26843068
[TBL] [Abstract][Full Text] [Related]
8. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D; Di Carlo D; Cozzi-Lepri A; Calcagno A; Borghi V; Gori C; Bertoli A; Gennari W; Bellagamba R; Castagna A; Latini A; Pinnetti C; Cicalini S; Saracino A; Lapadula G; Rusconi S; Castelli F; Di Giambenedetto S; Andreoni M; Di Perri G; Antinori A; Mussini C; Ceccherini-Silberstein F; Monforte AD; Perno CF; Santoro MM;
Antivir Ther; 2019; 24(5):321-331. PubMed ID: 30977466
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
10. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
Elvstam O; Medstrand P; Yilmaz A; Isberg PE; Gisslén M; Björkman P
PLoS One; 2017; 12(7):e0180761. PubMed ID: 28683128
[TBL] [Abstract][Full Text] [Related]
11. Cumulative HIV Viremia Copy-Years and Hypertension in People Living with HIV.
Xu Y; Chen X; Wijayabahu A; Zhou Z; Yu B; Spencer EC; Cook RL
Curr HIV Res; 2020; 18(3):143-153. PubMed ID: 32003696
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
13. Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.
Olson AD; Walker AS; Suthar AB; Sabin C; Bucher HC; Jarrin I; Moreno S; Perez-Hoyos S; Porter K; Ford D;
J Acquir Immune Defic Syndr; 2016 Sep; 73(1):100-8. PubMed ID: 27116045
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
[TBL] [Abstract][Full Text] [Related]
15. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
16. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
18. Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.
Wirden M; Todesco E; Valantin MA; Lambert-Niclot S; Simon A; Calin R; Tubiana R; Peytavin G; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2015 Aug; 70(8):2347-53. PubMed ID: 25921516
[TBL] [Abstract][Full Text] [Related]
19. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.
Gianotti N; Galli L; Racca S; Salpietro S; Cossarini F; Spagnuolo V; Barda B; Canducci F; Clementi M; Lazzarin A; Castagna A
J Antimicrob Chemother; 2012 Jan; 67(1):213-7. PubMed ID: 21987242
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
